We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prostate Cancer: OS AND RPFS BENEFITS IN CHEMO-NAIVE MCRPC.
- Authors
So, Alan
- Abstract
The article focuses on the results of the COU-AA-302 randomized trial which use abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). It says that AA has shown beneficial activity in patients with mCRPC as well as disease progression and clinical changes. It mentions that the U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of AA in mCRPC patient due to its survival benefit.
- Subjects
UNITED States; CANADA; DRUG efficacy; PROSTATE cancer treatment; RANDOMIZED controlled trials; DRUG approval; UNITED States. Food &; Drug Administration; CANADA. Health Canada
- Publication
Oncology Exchange, 2012, Vol 11, Issue 3, p31
- ISSN
1705-2394
- Publication type
Article